#kidney disease

A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco

Hepatitis C affects more than just the liver. Hep C can have serious health impacts long before there are signs of advanced liver disease.

Compared with their HIV-negative peers, HIV-positive individuals have higher rates of treatment for a host of health problems.

Highlights from HIV and hepatitis C research presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston

March is National Kidney Month, and an opportune time to look at hepatitis C and the kidneys.

A pooled analysis of numerous studies found the safety and efficacy of the regimen was comparable between those under and those over 65.

The hepatitis C regimen was tested in a small group with severe kidney impairment.

A promising new regimen that will address unmet needs for this population is poised for FDA approval.

An analysis of forty-two clinical trials of all the approved direct acting antiviral HCV regimens.

A hep C cure in those with HIV is tied to a lower rate of death, AIDS-defining illnesses, advanced cirrhosis and liver cancer.

The liver disease non-alcoholic steatohepatitis (NASH) is tied to kidney disease.

Among people with HIV, injection drug users have a higher rate of end-stage liver and kidney disease.

Curing hepatitis C virus (HCV) is associated with a reduced risk of death, kidney disease and diabetes.

American singer, songwriter and performer Natalie Cole died December 31, 2015

Hepatitis C treatment for those who also have HIV, advanced liver disease or other major health challenges is a delicate science.